Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Brexucabtagene Autoleucel plus Dasatinib for the Treatment of Relapsed or Refractory B Acute Lymphoblastic Leukemia

Trial Status: active

This phase Ib trial tests how well brexucabtagene autoleucel and dasatinib work in treating patients with B acute lymphoblastic leukemia that has come back after a period of improvement (relapsed) or that does not respond to treatment or that has not responded to previous treatment (refractory). Brexucabtagene autoleucel injection is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. It works by causing the body's immune system (a group of cells, tissues, and organs that protects the body from attack by bacteria, viruses, cancer cells, and other substances that cause disease) to fight the cancer cells. Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving brexucabtagene autoleucel followed by dasatinib may work better in treating patients with B acute lymphoblastic leukemia.